GLP-1 agonists are medications that lower levels of glucagon (a hormone that raises blood sugar), boost production of the digestive hormone insulin, and slow down how quickly your stomach empties
Diabetes Care, 48 (7), e93e93
Compared to GIP, which has normal secretion but poor response in patients with T2D, GLP-1, which has low secretion but preserved response, is an important target in the development of antidiabetic drugs
No injections, no refrigeration, no fasting requirements
Somatostatin, secreted from pancreatic -cells, acts as an inhibitory paracrine to suppress glucagon release from pancreatic -cells, and specific blockade of SSRT2 eliminates the inhibitory effect of GLP-1 on glucagon secretion
In vitro assays show relatively balanced GLP-1 and glucagon receptor activity, with stronger GIP receptor potency reported in some assay systems